The Europe deep brain simulation market is expected to grow from US$ 169.14 million in 2022 to US$ 319.88 million by 2030. It is estimated to grow at a CAGR of 8.3% from 2022 to 2030.
Based on product, the Europe deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. In 2022, the dual channel deep brain stimulator segment registered the largest share in the Europe deep brain simulation market.
Based on application, the Europe deep brain simulation market is segmented into Parkinson’s disease, tremor, dystonia, epilepsy, Alzheimer’s disease, and others. In 2022, the Parkinson’s disease segment registered the largest share in the Europe deep brain simulation market.
Based on end user, the Europe deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the largest share in the Europe deep brain simulation market.
Based on country, the Europe deep brain simulation market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. In 2022, Germany segment registered the largest share in the Europe deep brain simulation market.
Abbott Laboratories, Aleva Neurotherapeutics SA, Boston Scientific Corp, Medtronic Plc, and Newronika SpA are some of the leading companies operating in the Europe deep brain simulation market.
Reasons to Buy
Increasing Demand for Minimally Invasive Surgery Drive Europe Deep Brain Simulation Market
Deep brain stimulation is a minimally invasive targeted surgery used to treat movement disorders in dystonia, Parkinson's disease, and essential tremor. Minimally invasive surgeries (MIS) offer several advantages over traditional surgical techniques. MIS minimizes trauma to the body, reduces postoperative pain, increases recovery speed, and improves outcomes. Robotic procedures represent the latest evolution in minimally invasive procedures, providing surgeons with precision equipment that uses the same small incisions used in traditional laparoscopy. MIS leads to less blood loss, less analgesic use, and shorter postoperative hospital stay than open surgery. In addition, minimally invasive surgery indicates a higher accuracy rate than traditional surgical methods. Also, these procedures require tiny incisions large enough to insert thin tubes and cameras. These benefits of MIS are increasing inpatients and have encouraged older patients who face high operative morbidity and mortality to seek surgery. Thus, the rising demand for minimally invasive surgeries due to their advantages bolsters the Europe deep brain stimulation (DBS) market growth.Europe Deep Brain Simulation Market Overview
In the medical field, neurosurgery requires advanced equipment and highly qualified medical professionals. German neurosurgeons are highly qualified specialists; they follow the latest protocols and surgical procedures. Neurology centers in Germany have the most modern diagnostic and minimally invasive surgical devices that meet international quality standards. According to a study published at Charité - Universitätsmedizin Berlin entitled “Deep brain stimulation in Parkinson's: A new algorithm to adjust stimulation settings has been developed,” Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's. Approximately 400,000 people were affected with the disease in Germany in December 2022, and the numbers are increasing due to demographic aging. More and more people, including younger people, suffer from neurodegenerative diseases; in Germany, more than 2 million people have dementia or Parkinson's. According to the German Association for Alzheimer's Patients, in 2020, 9,450 people died from Alzheimer's, recording the highest figure. The increase in hospitalizations and deaths with Alzheimer's diagnosis is highly dependent on the aging population in Germany. People aged 65 and above increased by ~33% between and reached 18.3 million in 2020. Therefore, the aging population results in growing neurological disorders, which is expected to boost the market growth in the coming years.Europe Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Million)
Europe Deep Brain Simulation Market Segmentation
The Europe deep brain simulation market is segmented into product, application, end user, and country.Based on product, the Europe deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. In 2022, the dual channel deep brain stimulator segment registered the largest share in the Europe deep brain simulation market.
Based on application, the Europe deep brain simulation market is segmented into Parkinson’s disease, tremor, dystonia, epilepsy, Alzheimer’s disease, and others. In 2022, the Parkinson’s disease segment registered the largest share in the Europe deep brain simulation market.
Based on end user, the Europe deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the largest share in the Europe deep brain simulation market.
Based on country, the Europe deep brain simulation market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. In 2022, Germany segment registered the largest share in the Europe deep brain simulation market.
Abbott Laboratories, Aleva Neurotherapeutics SA, Boston Scientific Corp, Medtronic Plc, and Newronika SpA are some of the leading companies operating in the Europe deep brain simulation market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe deep brain simulation market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe deep brain simulation market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the deep brain simulation market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Deep Brain Simulation Market Landscape
5. Europe Deep Brain Simulation Market - Key Industry Dynamics
6. Deep Brain Simulation Market - Europe Market Analysis
7. Europe Deep Brain Simulation Market - Revenue and Forecast to 2030 - by Product
8. Europe Deep Brain Simulation Market - Revenue and Forecast to 2030 - by Application
9. Europe Deep Brain Simulation Market - Revenue and Forecast to 2030 - by End User
10. Europe Deep Brain Simulation Market - Country Analysis
11. Pre & Post Covid-19 Impact
12. Europe Deep Brain Simulation Market Industry Landscape
13. Europe Deep Brain Simulation Market, Key Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Aleva Neurotherapeutics SA
- Boston Scientific Corp
- Medtronic Plc
- Newronika SpA
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 95 |
Published | October 2023 |
Forecast Period | 2022 - 2030 |
Estimated Market Value in 2022 | 169.14 Million |
Forecasted Market Value by 2030 | 319.88 Million |
Compound Annual Growth Rate | 8.3% |
Regions Covered | Europe |
No. of Companies Mentioned | 5 |